
LAVA Therapeutics NV
NASDAQ:LVTX

Operating Margin
LAVA Therapeutics NV
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
NL |
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
32.9m USD |
-382%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
344.4B USD |
29%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
156.2B USD |
22%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
132.7B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
130.9B USD |
40%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
122.2B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65.6B USD |
30%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
34.6B EUR |
-1%
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on LAVA Therapeutics NV's most recent financial statements, the company has Operating Margin of -381.8%.